The purpose of this study is to compare the results of vision tests that are algorithmically derived and delivered through a virtual reality headset with those delivered through the existing technology standards (eg. Humphrey for field tests). Tests that the researchers...

This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.

This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD. This study is a double-masked, sham-controlled, parallel design prospective, mul...

This study proposes to use a new instrument (AO-OCT/AF: adaptive optics - optical coherence tomography/autofluorescence) combined with a data processing method to image the retinal pigment epithelium (RPE) of the eye in normal subjects and in subjects with age-related m...

AMD affects 15 million Americans, with 200,000 new advanced cases diagnosed each year. AMD is the leading cause of blindness in this country, from either the “dry” or “wet” advanced forms. At present, there is no treatment for dry AMD. Besides bl...

The purpose of this study is to learn more about age-related macular degeneration (AMD) by using a new investigational technology, AO-(adaptive optics) OCT (optical coherence tomography) with hyperspectral autofluorescence (AF). While currently there is no cure for AMD,...

Age-related macular degeneration (AMD) is the leading cause of blindness in our country, and heart attack and stroke are leading causes of death. We have discovered that AMD and these lethal systemic diseases may be linked by a special form of AMD called “reticula...